IP Library Granted Patent US 7,807,390
Granted Patent B2
US 7,807,390 · App. 11/970,276 · Granted Oct 5, 2010

G-protein coupled receptor ligands and methods

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,807,390
App. No.
11/970,276
Granted
Oct 5, 2010
Kind
B2
Abstract

The present invention relates to RF-amide peptides and their use for treating, preventing and curing neurological and metabolic medical disorders. The invention also relates to methods for modulating a G-protein coupled receptor and for identifying substances which modulate the receptor.

Claims (20)

1. A method for identifying an agonist or antagonist of a human SP9155 receptor that modulates the ability of a polypeptide ligand comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4-11 and 13-18, wherein the carboxy-terminus of said polypeptide ligand is amidated, to bind to said receptor, comprising:

(a) contacting the SP9155 receptor or a ligand-binding fragment thereof, which receptor or fragment thereof is capable of binding a polypeptide ligand comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4-11 and 13-18, wherein the carboxy-terminus of said polypeptide ligand is amidated, in the presence of a known amount of labeled polypeptide ligand for the SP9155 receptor or ligand-binding fragment thereof, wherein said polypeptide ligand comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 4-11 and 13-18, wherein the carboxy-terminus of said polypeptide ligand is amidated, with a sample to be tested for the presence of said agonist or antagonist; and

(b) measuring the amount of the ligand specifically bound to the receptor;

whereby the sample is identified as containing said antagonist or an agonist by measuring substantially reduced binding of the labeled ligand to the receptor, compared to what would be measured in the absence of the sample.

2. The method of claim 1 wherein the polypeptide ligand is a carboxy-terminally amidated polypeptide comprising an amino acid sequence selected from SEQ ID NOs: 5-11 and 14-18.

3. The method of claim 1 wherein the receptor comprises the amino acid sequence of SEQ ID NO: 2.

4. The method of claim 1 wherein the source of the receptor is a membrane isolated from a mammalian cell comprising said receptor.

5. The method of claim 1 wherein the polypeptide ligand is a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 5-11 and 14-18 wherein the carboxy-terminus of said polypeptide ligand is amidated.

6. The method of claim 3 wherein the receptor consists of amino acid sequence set forth in SEQ ID NO: 2.

7. The method of claim 1 wherein the polypeptide ligand comprises the amino acid sequence set forth in SEQ ID NO: 5; wherein the ligand is a carboxy-terminally amidated polypeptide.

8. The method of claim 7 wherein the polypeptide ligand consists of the amino acid sequence set forth in SEQ ID NO: 5; wherein the ligand is a carboxy-terminally amidated polypeptide.

9. The method of claim 1 wherein the polypeptide ligand comprises the amino acid sequence set forth in SEQ ID NO: 8; wherein the ligand is a carboxy-terminally amidated polypeptide.

10. The method of claim 9 wherein the polypeptide ligand consists of the amino acid sequence set forth in SEQ ID NO: 8; wherein the ligand is a carboxy-terminally amidated polypeptide.

11. The method of claim 1 wherein the polypeptide ligand comprises the amino acid sequence set forth in SEQ ID NO: 9; wherein the ligand is a carboxy-terminally amidated polypeptide.

12. The method of claim 11 wherein the polypeptide ligand consists of the amino acid sequence set forth in SEQ ID NO: 9; wherein the ligand is a carboxy-terminally amidated polypeptide.

13. The method of claim 1 wherein the polypeptide ligand comprises the amino acid sequence set forth in SEQ ID NO: 10; wherein the ligand is a carboxy-terminally amidated polypeptide.

14. The method of claim 13 wherein the polypeptide ligand consists of the amino acid sequence set forth in SEQ ID NO: 10; wherein the ligand is a carboxy-terminally amidated polypeptide.

15. The method of claim 1 wherein the polypeptide ligand comprises the amino acid sequence set forth in SEQ ID NO: 11; wherein the ligand is a carboxy-terminally amidated polypeptide.

16. The method of claim 15 wherein the polypeptide ligand consists of the amino acid sequence set forth in SEQ ID NO: 11; wherein the ligand is a carboxy-terminally amidated polypeptide.

17. The method of claim 15 wherein the receptor comprises the amino acid sequence set forth in SEQ ID NO: 2.

Assignments (1)
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →